Compugen Ltd. (CGEN) is a clinical-stage immuno-oncology biotechnology company headquartered in Holon, Israel, listed on the Nasdaq. With shares recently trading near $2.65, a move to $5 would represent an increase of roughly 89%, placing the level squarely in line with the Wall Street consensus price target of approximately $4.60 to $5.00. That makes $5 a natural, widely discussed benchmark rather than an arbitrary figure.
Investors asking whether CGEN can reach $5 are effectively asking whether the company's drug pipeline and its lucrative licensing deals can justify a substantial re-rating of a stock that has already gained more than 60% over the past year.
Compugen develops antibody-based cancer immunotherapies using its computational discovery platform. Its most advanced fully owned asset, COM701, is an anti-PVRIG antibody being studied in ovarian cancer and other solid tumors. The company also has COM902, an anti-TIGIT antibody, and earlier-stage programs such as COM503, which targets the IL-18 pathway.
Much of the investment narrative, however, revolves around partnerships. Compugen has a license agreement with AstraZeneca (AZN) covering the PD-1/TIGIT bispecific antibody rilvegostomig, which is in Phase 3 development for non-small cell lung cancer, and a separate agreement with Gilead Sciences (GILD) for COM503 and other programs. It has also collaborated with Bristol Myers Squibb (BMY). These deals generate milestone and royalty revenue that have meaningfully shaped the company's financial results.
CGEN has a 52-week range of roughly $1.30 to $3.24, and the stock remains well below its recent peak even after a strong rally. From a technical analysis standpoint, the first significant hurdle on the way to $5 is the prior high near $3.24, which also aligns with a round-number supply zone around $3. A sustained close above that resistance level would be needed to establish a higher-long-term structure.
On the downside, the $2.30–$2.40 area has acted as a support level during recent pullbacks, with the broader $2 range serving as a psychological floor. Any path toward the $5 stock price target first requires the shares to hold current support and then break through the $3.24 resistance zone.
The bullish case centers on two catalysts. First, positive clinical data from COM701, particularly in ovarian cancer, could materially change how the market values the company's pipeline. Compugen has guided that interim analysis results for its ongoing COM701 program are expected around year-end 2026. Second, continued progress on the AstraZeneca-partnered rilvegostomig Phase 3 program could support expectations of future milestone payments and royalties.
The company's balance sheet also provides some runway, with total cash recently reported around $125 million, which helps fund development while the pipeline matures. A favorable outcome on any of these fronts could justify a re-rating toward the $5 area.
The primary risk is financial rather than scientific. Compugen's revenue is projected to decline sharply as large, lumpy milestone payments roll off, with consensus estimates pointing to a drop from roughly $73 million in 2025 to about $9 million in 2026. Analysts also forecast a swing to a net loss, with earnings per share (EPS) turning negative. This reliance on irregular milestone and royalty income makes revenue highly unpredictable.
Additional obstacles include the inherent risk of clinical-stage drug development, competition in the crowded TIGIT and PVRIG immunotherapy space, and the stock's elevated volatility, reflected in a beta well above the broader market. A trial setback or a disappointing data readout could quickly undermine the path toward higher price levels.
Wall Street remains broadly constructive. The consensus rating is a "Strong Buy," with an average 12-month price target near $4.60. Individual targets range from $4.00 on the low end to $6.00 on the high end. Notable recent actions include Leerink Partners lowering its target from $13 to $5 while maintaining a Buy rating, Lake Street raising its target from $5 to $6, and H.C. Wainwright maintaining a $4 target.
This range means the $5 objective sits almost exactly at the midpoint of analyst expectations, reinforcing that it is a realistic but far from guaranteed outcome. The downward revision of some targets in 2026 also reflects more cautious assumptions about revenue and execution, which investors should weigh carefully.
Traders looking for an objective way to track changing conditions in stocks like CGEN may find value in Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and exchange-traded funds (ETFs), generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and identify emerging market trends more efficiently. For those seeking a data-driven complement to their own research, exploring the AI Daily Buy/Sell Signals may be a useful next step.
A move to $5 for CGEN is plausible but not assured. It aligns closely with the consensus analyst price target and would likely require positive clinical data from COM701, continued progress on partnered programs, and a successful breach of the $3.24 resistance level. Against this, a projected revenue collapse, a return to net losses, and the ever-present risk of clinical failure represent meaningful hurdles. Investors monitoring the stock should watch for COM701 data readouts, updates from the AstraZeneca and Gilead collaborations, and whether the shares can hold the $2.30 support zone while building momentum toward $3.24.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | -1.32% | ||
| ORMP - CGEN | 40% Loosely correlated | +0.42% | ||
| ACET - CGEN | 37% Loosely correlated | -2.03% | ||
| MLTX - CGEN | 37% Loosely correlated | -0.69% | ||
| AXON - CGEN | 36% Loosely correlated | +2.20% | ||
| RCUS - CGEN | 36% Loosely correlated | +2.78% | ||
More | ||||